In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...

InflaRx ( ($IFRX) ) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma ...

Gastroenterology specialists Dr Andy Li and Dr Jessica Gurung outline a rational approach to investigating recurrent ...

InflaRx presented data analyses from a terminated Phase 3 study on the potential treatment for rare skin condition.

German drug developer InflaRx, which is developing anti-inflammatory therapeutics by targeting the complement system, has ...

InflaRx had been pursuing development of vilobelimab in other indications beyond COVID, but the company’s hopes for the asset ...

InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa ...

InflaRx (IFRX) outlined multiple data analyses of the Phase 3 study for vilobelimab in pyoderma gangrenosum, which was terminated earlier this ...